Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
Related to this article
A rituximab biosimilar has been approved by the FDA.
Overall survival was the sole US primary end point of the phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab and was not met.
Advertisement
Advertisement
Trending on OncLive
1
Phase 1 Data Set the Stage for Further Exploration of Cevostamab in R/R Myeloma
2
Dr Mulvey on Real-World Treatment Discontinuation Data for First-Line BTK Inhibitors in CLL
3
Dr Cohen on Phase 1 Efficacy Data for Cevostamab in R/R Myeloma
4
Docirbrutinib Yields High Response Rates in MCL and CLL
5